Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990297 | 0.83 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL5603398 | 0.81 | KMT2A (0.60) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL4167897 | 0.81 | KMT2A (0.54) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL43494 | 0.80 | CYP2C19 (0.57) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL2494960 | 0.79 | KMT2A (0.59) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL7329851 | 0.78 | TSHR (0.57) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL21887012 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1MAPTHTT | |
| Ethylene SCHEMBL11190134 | 0.77 | CYP2C19 (0.54) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL9667193 | 0.77 | KMT2A (0.51) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL10815212 | 0.77 | CYP2C19 (0.57) | ALDH1A1KMT2AMEN1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| CN-1918133-A | Alpha-4 integrin mediated cell adhesion inhibitors for the treatment or prevention of inflammatory diseases | TANABE SEIYAKU CO (JP) | 2007-02-21 | — | — | CN | disclosed |
| EP-0280156-B1 | PROCESS FOR THE PREPARATION OF ACETOACETYLARYLAMIDES-HETEROARYLAMIDES RESPECTIVELY OF DEACTIVED AROMATIC COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0280156-A2 | Process for the preparation of acetoacetylarylamides-heteroarylamides respectively of deactived aromatic compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | ALDH1A1 431/4885KMT2A 4139/4885MEN1 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.